Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 403 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, intranasal Clear all
Recruiting Phase 1Phase 2 Interventional

Intranasal Insulin for Treatment of Alcohol Use Disorder

NCT05988632
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Regular Human Insulin then Placebo, Placebo then Regular Human Insulin
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Cocaine During Phendimetrazine Maintenance

NCT02522325
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Phendimetrazine, Cocaine, Placebo
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 4, 2026, 9:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Arcadia, California • Los Angeles, California • Newport Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin in Parkinson's Disease

NCT04251585
View directory record Official record
Conditions
Parkinson Disease
Interventions
Regular Novolin R, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
41 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

NCT03781804
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
OPN-375
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
46
States / cities
Gilbert, Arizona • Bakersfield, California • Folsom, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Wellness Behaviors as a Function of Oxytocin vs Placebo

NCT01929161
View directory record Official record
Conditions
Sustained Positive Emotions, Sustained Positive Behavior Change
Interventions
Oxytocin, Placebo (for oxytocin), Lovingkindness Meditation, Mindfulness Meditation
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
35 Years to 64 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 4, 2026, 9:02 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults

NCT02225600
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
40 IU Intranasal Oxytocin, Placebo, 24 IU intranasal Oxytocin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Oxytocin, Alcohol Craving, and Intimate Partner Aggression

NCT03046836
View directory record Official record
Conditions
Alcohol Use
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

NCT01767909
View directory record Official record
Conditions
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Insulin (Humulin® R U-100), Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis

NCT02025725
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Single Dose Intranasal Oxytocin and Cognitive Effects in Autism

NCT02493426
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
5 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children

NCT03337035
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
intranasal oxytocin, oral probiotics, oral placebo
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 25 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 2 Interventional

Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia

NCT01217788
View directory record Official record
Conditions
Social Phobia, Social Anxiety Disorder
Interventions
PH94B intranasal spray
Drug
Lead sponsor
Pherin Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

NCT02462161
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Insulin aspart, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Assess the Safety of a New Influenza Vaccine

NCT01104493
View directory record Official record
Conditions
Healthy
Interventions
Monovalent Frozen FluMist®, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin for Posttraumatic Stress Disorder

NCT04044534
View directory record Official record
Conditions
PTSD
Interventions
Intranasal insulin, Placebo
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 4, 2026, 9:02 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

NCT04909021
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)
Biological · Other
Lead sponsor
Meissa Vaccines, Inc.
Industry
Eligibility
6 Months to 36 Months
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)

NCT01908205
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
Holland Bloorview Kids Rehabilitation Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 4, 2026, 9:02 PM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

NCT05422612
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis

NCT02025751
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 4, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

NCT07222670
View directory record Official record
Conditions
Viral Respiratory Infection, Viral Respiratory Illnesses
Interventions
INNA-051, Placebo
Drug · Other
Lead sponsor
ENA Respiratory Pty Ltd
Industry
Eligibility
18 Years to 45 Years
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
5
States / cities
Baltimore, Maryland • Bethesda, Maryland • Raleigh, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 9:02 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment

NCT06805994
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Microbial Colonization, Pediatric Infection, S. Aureus Colonization, Microbial Transplant
Interventions
Nasal Microbiota Transplant (NMT), Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin, Emotions and Mirror Neurons

NCT02228031
View directory record Official record
Conditions
Social Cognition, Expressed Emotion
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 4, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

NCT02898454
View directory record Official record
Conditions
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Interventions
Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 4, 2026, 9:02 PM EDT